ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,570Medicare Part D Prescriptions Filled, Including Refills

Rank: 178 out of 1692

$543K Total Retail Price of All Prescriptions

Rank: 209 out of 1692

519 Patients Receiving at Least One Drug in Part D
70%Patients 65 Years and Older
46% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Virginia
Lower avg

Schedule Two
Controlled Substances

2% of this provider’s 519 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

19% of this provider’s 519 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

2% of this provider’s 7,544 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Virginia
HYDROCODONE-ACETAMINOPHEN 531 308 S3 1 6
OMEPRAZOLE 408 272 2 5
SIMVASTATIN 393 314 3 1
AMLODIPINE BESYLATE 386 277 4 3
LISINOPRIL 362 270 5 2
LEVOTHYROXINE SODIUM 342 286 6 4
METFORMIN HCL 244 186 7 8
HYDROCHLOROTHIAZIDE 238 199 8 9
FUROSEMIDE 237 197 9 7
METOPROLOL TARTRATE 228 177 10 10
ATORVASTATIN CALCIUM 178 115 11 11
LISINOPRIL-HYDROCHLOROTHIAZIDE 176 154 12 19
NEXIUM 158 116 13 25
POTASSIUM CHLORIDE 156 80 14 20
ZOLPIDEM TARTRATE 154 87 15 23
GLIMEPIRIDE 144 122 16 32
ATENOLOL 136 126 17 15
GABAPENTIN 121 72 18 13
LOSARTAN POTASSIUM 115 108 19 17
AMLODIPINE BESYLATE-BENAZEPRIL 103 96 20 67
PANTOPRAZOLE SODIUM 101 50 21 39
RANITIDINE HCL 99 55 22 28
WARFARIN SODIUM 99 68 22 14
PROAIR HFA 99 67 22 40
MELOXICAM 97 68 25 41
CITALOPRAM HBR 91 50 26 21
LOSARTAN-HYDROCHLOROTHIAZIDE 80 46 27 38
DIOVAN 75 75 28 42
METFORMIN HCL ER 75 70 28 49
PRAVASTATIN SODIUM 73 38 30 12
SERTRALINE HCL 73 42 30 22
TAMSULOSIN HCL 73 57 30 31
TRAMADOL HCL 71 45 33 16
CEFUROXIME 63 45 34 153
JANUVIA 60 60 35 72
GLIPIZIDE ER 60 51 35 87
METOPROLOL SUCCINATE 60 35 35 18
DOXAZOSIN MESYLATE 60 53 35 83
TRAZODONE HCL 58 24 39 33
CYMBALTA 56 34 40 51
VENLAFAXINE HCL ER 55 41 41 84
MECLIZINE HCL 54 49 42 124
SPIRIVA 54 31 42 44
FLUTICASONE PROPIONATE 53 32 44 27
DICLOFENAC SODIUM 53 40 44 75
FINASTERIDE 53 49 44 99
ISOSORBIDE MONONITRATE ER 52 52 47 55
DONEPEZIL HCL 50 50 48 29
ALLOPURINOL 50 35 48 30
CLOPIDOGREL 50 43 48 43
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 12, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.